Product Description
BNT212 is a CAR-T cell therapy directed against the tumor antigen Claudin 18.2 (CLDN18.2), which is expressed in numerous epithelial solid tumors, including gastric, pancreatic, esophageal, ovarian and lung tumors. (Sourced from: https://www.biontech.com/int/en/home/pipeline-and-products/pipeline.html#bnt212-pancreatic-cancer)
Mechanisms of Action: CAR-T, CLDN18.2
Novel Mechanism: Yes
Modality: Autologous CAR-T
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioNTech
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/04/2021 |
News Article |
2021 Insights on the CAR-T Cell Therapy Global Market - Overview of Clinical Trials |
|
06/04/2021 |
News Article |
Worldwide CAR-T Cell Therapy Industry - Featuring Aleta BioTherapeutics, Atara Biotherapeutics and BioNTech Among Others |
|
01/07/2021 |
News Article |
Worldwide Industry for CAR-T Cell Therapy (2021 to 2027) - Players Profiled Include Aleta BioTherapeutics, Anixa Biosciences and BioNTech Among Others |
|
01/05/2021 |
News Article |
Outlook on the CAR-T Cell Therapy Global Market to 2027 - Capitalize on Emerging Trends |